Skip to main content
Premium Trial:

Request an Annual Quote

Discover Labs Obtains FDA Emergency Use Authorization for RT-PCR COVID Test

NEW YORK – Austin, Texas-based testing service provider Discover Labs obtained Emergency Use Authorization from the US Food and Drug Administration last week for a PCR assay to detect SARS-CoV-2.

Called the Discover Labs COVID-19 Assay, the RT-PCR test is for the qualitative detection of nucleic acids from SARS-CoV-2 in nasal, nasopharyngeal, and oropharyngeal swab specimens from individuals suspected of COVID-19 infection by their healthcare provider.

Testing is limited to Discover Labs' CLIA facilities, which are authorized to perform high-complexity testing, according to the FDA's letter of authorization.

In addition to the COVID-19 assay, Discover Labs offers a 34-target respiratory pathogen panel, as well as a service that reflexes negative COVID-19 tests to the RPP, according to the lab's website. It also offers a test for urinary tract and sexually transmitted infections that detects 25 pathogens and 20 antibiotic resistance markers, a wound infection test that detects 22 pathogens and 20 antibiotic resistance markers, and a 32-target women's health assay.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.